Skip to content

REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2019-08-14

What REGENERX BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2019-08-14 (fiscal Q2 2019): 36 published measures, 111 facts as tagged in accession 0001144204-19-040034.

This filing

Form
10-Q (quarterly report)
Filed
2019-08-14
Fiscal period
fiscal Q2 2019
Accession
0001144204-19-040034 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All REGENERX BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-301,263,698USD
At 2018-12-31281,040USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-06-303,020,136USD
At 2018-12-312,493,093USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-30-1,756,438USD
At 2019-03-31-1,956,741USD
At 2018-12-31-2,212,053USD
At 2018-06-30-2,255,733USD
At 2018-03-31-1,948,036USD
At 2017-12-31-4,116,292USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-06-301,170,710USD
At 2018-12-31237,261USD
At 2018-06-30662,764USD
At 2017-12-31181,708USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-388,448USD91
2019-01-01 to 2019-06-30-720,899USD181
2019-01-01 to 2019-03-31-332,451USD90
2018-04-01 to 2018-06-30-367,874USD91
2018-01-01 to 2018-06-30-1,353,738USD181
2018-01-01 to 2018-03-31-985,864USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-607,176USD181
2018-01-01 to 2018-06-30-462,791USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-04-01 to 2019-06-3019,190USD91
2019-01-01 to 2019-06-3038,381USD181
2018-04-01 to 2018-06-3012,504USD91
2018-01-01 to 2018-06-3031,286USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-06-301,540,625USD181
2018-01-01 to 2018-06-30943,847USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-106,685,242USD
At 2018-12-31-105,881,777USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2019-04-01 to 2019-06-30131,264,736shares91
2019-01-01 to 2019-06-30130,426,134shares181
2018-04-01 to 2018-06-30119,637,282shares91
2018-01-01 to 2018-06-30115,671,709shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2019-04-01 to 2019-06-30131,264,736shares91
2019-01-01 to 2019-06-30130,426,134shares181
2018-04-01 to 2018-06-30119,637,282shares91
2018-01-01 to 2018-06-30115,671,709shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2019-04-01 to 2019-06-300USD/shares91
2019-01-01 to 2019-06-30-0.01USD/shares181
2018-04-01 to 2018-06-300USD/shares91
2018-01-01 to 2018-06-30-0.01USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2019-04-01 to 2019-06-300USD/shares91
2019-01-01 to 2019-06-30-0.01USD/shares181
2018-04-01 to 2018-06-300USD/shares91
2018-01-01 to 2018-06-30-0.01USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-04-01 to 2019-06-300USD91
2019-01-01 to 2019-06-300USD181
2018-04-01 to 2018-06-300USD91
2018-01-01 to 2018-06-300USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-06-3086USD
At 2018-12-311,418USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-06-30170,062USD181
2018-01-01 to 2018-06-30120,345USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-351,946USD91
2019-01-01 to 2019-06-30-674,807USD181
2018-04-01 to 2018-06-30-342,108USD91
2018-01-01 to 2018-06-30-706,242USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-301,214,769USD
At 2018-12-31273,870USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-04-01 to 2019-06-3039,447USD91
2019-01-01 to 2019-06-3049,037USD181
2018-04-01 to 2018-06-3025,766USD91
2018-01-01 to 2018-06-3064,592USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-30243,964USD
At 2018-12-31315,006USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-06-3058,319USD
At 2018-12-3192,433USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-30371,136USD91
2019-01-01 to 2019-06-30713,188USD181
2018-04-01 to 2018-06-30354,612USD91
2018-01-01 to 2018-06-30737,528USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-04-01 to 2019-06-3026,337USD91
2019-01-01 to 2019-06-3041,641USD181
2018-04-01 to 2018-06-3018,854USD91
2018-01-01 to 2018-06-3037,699USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-30131,506,494shares
At 2018-12-31128,432,478shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2019-06-3043,091USD
At 2019-01-0160,000USD
At 2018-12-310USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2019-06-3047,226USD
At 2019-01-0165,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-06-3099,253USD
At 2018-12-3197,921USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-06-305,752USD
At 2018-12-315,752USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-06-3061,658USD
At 2018-12-3191,058USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-06-3044,059USD
At 2018-12-3136,609USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-388,448USD91
2019-01-01 to 2019-06-30-720,899USD181
2018-04-01 to 2018-06-30-367,874USD91
2018-01-01 to 2018-06-30-1,353,738USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-388,448USD91
2019-01-01 to 2019-06-30-803,465USD181
2018-04-01 to 2018-06-30-367,874USD91
2018-01-01 to 2018-06-30-1,353,738USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30344,799USD91
2019-01-01 to 2019-06-30671,547USD181
2018-04-01 to 2018-06-30335,758USD91
2018-01-01 to 2018-06-30699,829USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-01-01 to 2019-06-301,332USD181
2018-01-01 to 2018-06-301,421USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-36,502USD91
2019-01-01 to 2019-06-30-46,092USD181
2018-04-01 to 2018-06-30-25,766USD91
2018-01-01 to 2018-06-30-647,496USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-34,114USD181
2018-01-01 to 2018-06-30-27,806USD181

Inspect the source

Entity
REGENERX BIOPHARMACEUTICALS, INC. / CIK 0000707511
Captured
SEC response SHA-256
ffc4eb5988984f6f0271e31d8cf8024b0343b848cad3a73089a36cab28954e4d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000707511.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))